Purpose: Using real-world evidence, this study aimed to identify elderly nasopharyngeal carcinoma (NPC) patients who would benefit from chemotherapy. Methods and materials: 1714 elderly NPC patients between April 2007 and December 2017 were identified. Recursive partitioning analysis (RPA) was used to generate risk-stratified outcomes. Prognostic factors were performed for individual comparisons of different risk groups to assess chemotherapy benefits. Results: The median follow-up was 59.3 (0.39–170.09) months. Epstein Barr virus (EBV) DNA and T stage were included in the RPA-generated risk stratification, categorizing patients into a good-prognosis group (EBV DNA ≤ 4000 copies/mL & T1–2), and a poor-prognosis group (EBV DNA ≤ 4000 copies/mL & T3–4 and EBV DNA > 4000 copies/mL & any T). Overall survival (OS) was significantly higher in the good-prognosis group compared with the training set (HR = 0.309, 95% CI 0.184–0.517; P < 0.001), and validated in the testing set (HR = 0.276, 95% CI 0.113–0.670; P = 0.002). In the poor-prognosis group, a significantly improved OS for chemoradiotherapy (CRT) compared with RT alone was observed (HR = 0.70, 95% CI 0.55–0.88; P = 0.003). Patients who received induction chemotherapy (IC) + concurrent chemoradiotherapy (CCRT) and CCRT had a significantly improved OS compared with RT alone (IC + CCRT vs. RT alone: P = 0.002; CCRT vs. RT alone: P = 0.008) but not in the IC + RT group (P = 0.306). The 5-year OS for CRT versus RT-alone with ACE-27 scores of 0, 1 and 2 were 76.0% versus 70.0% (P = 0.014), 80.5% versus 68.2% (P = 0.150) and 58.5% versus 62.2% (P = 0.490), respectively; for those aged 60–64, 65–70 and ≥ 70 years old they were 80.9% versus 75.9% (P = 0.068), 73.3% versus 63.4% (P = 0.270) and 64.8% versus 67.1% (P = 0.820), respectively. Conclusions: For elderly NPC patients a simple screening cutoff for chemotherapy beneficiaries might be EBV DNA < 4000 copies/ml & T3–4 and EBV DNA ≥ 4000 copies/ml & any T, but not for those > 70 years old and with an ACE-27 score > 1. IC + CCRT and CCRT were effective forms of chemotherapy.
Purpose. To quantify the long-term evaluation of optic chiasma (OC) and/or optic nerve(s) (ONs) and to develop predictive models for radiation-induced optic neuropathy (RION) in nasopharyngeal carcinoma after intensity-modulated radiotherapy (IMRT). Methods and Materials. A total of 3,662 patients’ OC/ONs with full visual acuity and dosimetry data between 2010 and 2015 were identified. Critical dosimetry predictors of RION were chosen by machine learning and penalized regression for survival. A nomogram containing dosimetry and clinical variables was generated for predicting RION-free survival. Results. The median follow-up was 71.79 (2.63–120.9) months. Sixty-six eyes in 51 patients (1.39%) developed RION. Two patients were visual field deficient, and 49 patients had visual acuity of less than 0.1 (20/200). The median latency time was 36 (3–90) months. The 3-, 5-, and 8-year cumulative incidence of RION was 0.78%, 1.19%, and 1.97%, respectively. Dmax was the most critical dosimetry variable for RION (AUC: 0.9434, the optimal cutoff: 64.48 Gy). Patients with a Dmax ≥64.48 Gy had a significantly higher risk of RION (HR = 102.25; 95%CI, 24.86–420.59; ). Age (>44 years) (HR = 2.234, 95% CI = 1.233–4.051, p = 0.008), advanced T stage (T3 vs. T1-2: HR = 7.516, 95% CI = 1.725–32.767, ; T4 vs. T1-2: HR = 37.189, 95% CI = 8.796–157.266, ), and tumor infiltration/compression of the OC/ONs (HR = 4.572, 95% CI = 1.316–15.874, ) were significant clinical risk factors of RION. A nomogram comprising age, T stage, tumor infiltration/compression of the OC/ON, and Dmax significantly outperformed the model, with only Dmax predicting RION (C-index: 0.916 vs. 0.880, in the training set; 0.899 vs. 0.874, in the test set). The nomogram-defined high-risk group had a worse 8-year RION-free survival. Conclusions. In the IMRT era, Dmax <60 Gy is safe and represents an acceptable dose constraint for most NPC patients receiving IMRT. A reasonable trade-off for selected patients with unsatisfactory tumor coverage due to proximity to the optic apparatus would be Dmax <65 Gy. Caution should be exercised when treating elderly and advanced T-stage patients or those with tumor infiltration/compression of the OC/ON. Our nomogram shows strong efficacy in predicting RION.
Objective: This study aims to evaluate the risk stratification among elderly Nasopharyngeal carcinoma (NPC) patients (>= 60 years old) and select the beneficiaries from concurrent chemotherapy (CCRT) combined with induction chemotherapy (IC). Materials and Methods: A total of 909 elderly non-metastatic NPC patients treated with cisplatin- based CCRT or IC + CCRT between January 2007 and December 2016 were included. Prognostic nomograms were generated according to clinical characteristics and serum biomarkers. The survival outcomes of patients treated with CCRT versus IC + CCRT were compared in three well-matched risk groups (high, medium, and low risk) after PSM analysis. Benefit of IC in people older or younger than 70 years and effect of different IC regimens and cycles on prognosis were analyzed. Results: Nomograms of overall survival (OS) (C-index: 0.64, 95% CI, 0.61- 0.89) and disease special survival (DSS) (C-index: 0.65, 95% CI, 0.62- 0.71) showed good prognostic accuracy. The nomogram for DSS included variables of age, gender, ACE, EBV DNA, N stage, and T stage. OS included variables of age, smoking history, ACE, ALB, EBV DNA, N stage, and T stage. The corresponding 5 year OS rates of high, medium and low risk groups were 87.4%, 82.2%, and 60.9%, respectively (p < 0.001), while the 5 year DSS rates were 92.2%, 84.3%, and 69.0%, respectively (p < 0.001). In the high risk group, IC + CCRT led to significantly higher 5 year OS and DSS rate compared with CCRT (5 year OS rate, 73.5% versus 51.8%, p = 0.006; 5 year DSS rate, 81.4% versus 61.3%, p = 0.002). While in the medium and low risk groups, OS and DSS were not significantly different (OS: p = 0.259, 0.186; DSS: p = 0.29, 0.094). Subgroup analysis showed in the high risk group, only people younger than 70 years old could benefit from IC. TPF and IC cycles of three could lead to the best survival results. Conclusion: Compared with CCRT, OS, and DSS among high risk elderly patients were significantly improved by the addition of IC in patients younger than 70 years old. TPF and three IC cycles were recommended.
Purpose: Stereotactic body radiotherapy (SBRT) is a highly effective and well-tolerated treatment modality for peripherally located early-stage non-small cell lung cancer as well as pulmonary metastases. However, its feasibility and safety remain uncertain in patients with ultra-central (UC) lung tumors. This study aims to evaluate the efficacy and safety of SBRT in the management of UC lung malignancies. Methods: A systematic review of the available literature was conducted in accordance with the PRISMA guidelines, incorporating studies that reported both treatment-related side effects and therapeutic efficacy associated with SBRT for UC lung malignancies. Patient characteristics, prescription doses, local control (LC), overall survival (OS), and side effects information were extracted. Clinical outcomes were analyzed using the random-effects model. Meta-regression was conducted to determine the effect of various covariates on LC and OS outcomes. Results: Twenty-three articles with a total of 1,105 patients were included. Pooled 1- and 2-year LC rates were 93% (95% CI: 88–96%) and 84% (95% CI: 77–89%), respectively. Meta-regression demonstrated a significantly positive association between BED 10 and 1- and 2-year LC rates ( P = 0.001, P < 0.001, respectively), and a significantly negative association between PTV volume and 1- and 2-year LC ( P = 0.048, P = 0.030, respectively). Pooled 1- and 2-year OS rates were 81% (95% CI: 77–85%) and 58% (95% CI: 52–64%), respectively. Meta-regression revealed a significantly positive association between BED 10 and 1- and 2-year OS rates ( P = 0.025, P = 0.002, respectively), and a significantly negative association between PTV volume and 1- and 2-year OS ( P = 0.031, P < 0.001, respectively). The pooled rates of grade ≥ 3 and grade 5 treatment-related side effects were 9% (95% CI: 6–14%) and 2% (95% CI: 1–5%), respectively. Conclusion: This meta-analysis demonstrates that SBRT achieves favorable LC rates and is a relatively safe treatment for UC lung malignancies. Although the pooled rate of grade 5 side effects, at 2%, was within an acceptable range, vigilance remains essential. Further prospective research is warranted to verify our conclusions.
Purpose: Using real-world evidence, this study aimed to identify elderly nasopharyngeal carcinoma (NPC) patients who would benefit from chemotherapy.Methods and Materials: 1,714 elderly NPC patients between April 2007 and December 2017 were identified. Recursive partitioning analysis (RPA) was used to generate risk-stratified outcomes. Prognostic factors were performed for individual comparisons of different risk groups to assess chemotherapy benefits.Results: The median follow-up was 59.3 (0.39-170.09) months. Epstein Barr virus (EBV) DNA and T stage were included in the RPA-generated risk stratification, categorizing patients into a good-prognosis group (EBV DNA ≤ 4,000 copies/mL & T1-2), and a poor-prognosis group (EBV DNA ≤ 4,000 copies/mL & T3-4 and EBV DNA > 4,000 copies/mL & any T). Over survival (OS) was significantly higher in the good-prognosis group compared with the training set (HR = 0.309, 95% CI = 0.184-0.517; P < 0.001), and validated in the testing set (HR = 0.276, 95% CI = 0.113-0.670; P = 0.002). In the poor-prognosis group, a significantly improved OS for chemoradiotherapy (CRT) compared with RT alone was observed (HR = 0.70, 95% CI = 0.55-0.88; P = 0.003). Patients who received induction chemotherapy (IC) + concurrent chemoradiotherapy (CCRT) and CCRT had a significantly improved OS compared with RT alone (IC+CCRT vs. RT alone: P = 0.002; CCRT vs. RT alone: P = 0.008) but not in the IC+RT group (P = 0.306). The 5-year OS for CRT vs. RT-alone with ACE-27 scores of 0, 1 and 2 were 76.0% vs. 70.0% (P = 0.014), 80.5% vs. 68.2% (P = 0.150) and 58.5% vs. 62.2% (P = 0.490), respectively; for those aged 60-64, 65-70 and ≥70 years old they were 80.9% vs. 75.9% (P = 0.068), 73.3% vs. 63.4% (P = 0.270) and 64.8% vs. 67.1% (P = 0.820), respectively.Conclusions: For elderly NPC patients a simple screening cutoff for chemotherapy beneficiaries might be EBV DNA<4000 copies/ml & T3-4 and EBV DNA ≥4000 copies/ml & any T, but not for those >70 years old and with an ACE-27 score > 1. IC+CCRT and CCRT were effective forms of chemotherapy.
Background: This study analyzed the efficacy of multiple combined chemotherapy modalities on the long-term survival outcomes in stage II–IVA nasopharyngeal carcinoma (NPC) patients with undetectable pretreatment Epstein-Barr viral DNA (pre-DNA). Patients and methods: We retrospectively analyzed 2,440 patients with stage II–IVA NPC with undetectable pre-DNA. Patients received any of the following treatment modalities: intensity-modulated radiotherapy (IMRT) alone; concurrent chemoradiotherapy (CCRT); induction chemotherapy (IC) + CCRT; IC + IMRT; or CCRT + adjuvant chemotherapy (AC) at Sun Yat-sen University Cancer Center between 2009 and 2015. Propensity score matching (PSM) was performed to balance variables. Matched patients in different treatment subgroups were analyzed by comparing survival outcomes. Results: In the PSM cohorts, no significant differences were observed in disease-free survival (DFS), overall survival (OS), distant metastasis-free survival (DMFS), or locoregional relapse-free survival (LRRFS) between patients treated with IMRT combined with multiple chemotherapy modalities and those with IMRT alone (all P > 0.05). The estimated 5-year DFS, OS, DMFS, and LRRFS rates were 85.6% vs. 87.3% ( P = 0.33), 93.5% vs. 92.2% ( P = 0.64), 94.4% vs. 93.7% ( P = 0.96), and 92.0% vs. 94.0% ( P = 0.16), respectively. Similarly, no significant differences in 5-year DFS, OS, DMFS, or LRRFS were observed across subgroups receiving IMRT with or without concurrent chemotherapy (CC), IC followed by IMRT with or without CC, or CCRT with or without IC. However, among patients receiving CCRT with or without AC, the 5-year DFS (96.0% vs. 78.3%, P = 0.004), OS (98.0% vs. 88.1%, P = 0.027), and LRRFS (97.9% vs. 87.9%, P = 0.045) rates were significantly higher in patients without AC, whereas no significant difference was observed in DMFS (96.0% vs. 86.1%, P = 0.078). No significant differences in the survival outcomes of T3–4 stage and N2–3 disease were identified. Conclusions: In patients with stage II–IVA NPC with undetectable pre-treatment EBV DNA, the addition of chemotherapy to IMRT was not associated with a statistically significant improvement in survival, regardless of whether they received induction, concurrent, or adjuvant chemotherapy. Further prospective validation is required.